Thursday, October 22, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 17, 2026

13,000 strong: AIBC Eurasia 2026 sets the stage for a bigger 2027

View original at globenewswire.com
13,000 strong: AIBC Eurasia 2026 sets the stage for a bigger 2027 DUBAI, United Arab Emirates , Feb. 17, 2026 (GLOBE NEWSWIRE) -- Six years on since our intrepid 2021 launch in Dubai, and AIBC Eurasia shows no signs of slowing down…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • History will remember this decade as the one where technology's centre of power has shifted from West to East

    80% confidence

  • Most people don't know how to use crypto, creating an educational barrier that makes traditional marketing methods fail because they're not really trusted

    80% confidence

  • Free zones are no longer administrative hubs but innovation engines driving companies towards success

    80% confidence

  • We are living through a defining moment in human history where intelligence is no longer confined to the human mind

    80% confidence

  • Ambition without ethics is fragile, intelligence without leadership is dangerous. The future belongs to those who lead with values

    80% confidence

  • The industry is still in its infancy and the next wave of Web3 could help close the gap between crypto and everyday users

    80% confidence

  • RAK is no longer a place, but a platform for innovation where the goal is business nirvana - removing friction so innovators can focus on inventing and building the future

    80% confidence

  • Blockchain has superpowers that go far beyond fintech and should stabilize systems rather than replace them

    80% confidence

  • AIBC Eurasia 2027 is expected to host 14,000 delegates from MENA and international markets

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,426 source documents archived
Query this data → isubstrate.com